板 40(克隆），NR-1_Vaccinia virus

NR-19764?? Bacillus anthracis Gateway? Clone Set, Recombinant in Escherichia coli, Plate 40(Clones)|Bacillus anthracis|Bacillus anthracis Gateway? Clone Set, Recombinant in Escherichia coli, Plate 40|-80°C or colder|Pathogen Functional Genomics Resource Center at the J. Craig Venter InstituteAcknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Bacillus anthracis Gateway^? Clone Set, Recombinant in Escherichia coli, Plate 40, NR-19764."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.The Bacillus anthracis (B. anthracis) Gateway^? clone set consists of 58 plates which contain 5341 sequence validated clones from B. anthracis, strains Ames (5139 clones), Sterne (107 clones; contains plasmid pXO1 only) and A2012 (95 clones; contains plasmid pXO2 only) cloned in Escherichia coli (E. coli) DH10B-T1 cells. Each open reading frame was constructed in vector pDONR?221 (Invitrogen?) with a native start codon and no stop codon. The library was independently cloned and sequence verified by the Harvard Institute of Proteomics.Information related to the use of Gateway^? Clones can be obtained from Invitrogen?. Recombination was facilitated through a Harvard-modified attB substrate (attB-PCR product or a linearized attB expression clone) with an attP substrate (pDONR?221) to create an attL-containing entry clone. The entry clone contains recombinational cloning sites, attL1 and attL2 to facilitate gene transfer into a destination vector, M13 forward and reverse priming sites for sequencing and a kanamycin resistance gene for selection. Please refer to the Invitrogen? Gateway^? Technology Manual for additional details.Plate orientation and viability were confirmed for NR-19764.Each inoculated well of the 96-well plate contains approximately 60 ?L of E. coli culture (strain DH10B-T1) in Luria Bertani (LB) broth containing 50 ?g/mL kanamycin supplemented with 15% glycerol.Clone plates are replicated using a BioMek^? FX robot. Production in the 96-well format has increased risk of cross-contamination between adjacent wells. Individual clones should be purified (e.g. single colony isolation and purification using good microbiological practices) and sequence-verified prior to use. BEI Resources only confirms the clone plate orientation and viability of randomly picked clones. BEI Resources does not confirm or validate individual clone identities provided by the contributor.

NR-19718?? Vibrio cholerae Gateway? Clone Set, Recombinant in Escherichia coli, Plate 40(Clones)|Vibrio cholerae|Vibrio cholerae Gateway? Clone Set, Recombinant in Escherichia coli, Plate 40|-80°C or colder|Pathogen Functional Genomics Resource Center at the J. Craig Venter InstituteAcknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Vibrio cholerae Gateway^? Clone Set, Recombinant in Escherichia coli, Plate 40, NR-19718."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment. Production in the 96-well format has increased risk of cross-contamination between adjacent wells. Individual clones should be purified (e.g. single colony isolation and purification using good microbiological practices) and sequence-verified prior to use. BEI Resources does not confirm or validate individual mutants provided by the contributor. The Vibrio cholerae (V. cholerae) Gateway^? clone set consists of 46 plates which contain 3813 sequence validated clones from V. cholerae, strain El Tor N16961 cloned in Escherichia coli (E. coli) DH10B-T1 cells. Each open reading frame was constructed in vector pDONR?221 with a native start codon and stop codon. The library was independently cloned and sequence verified by the Harvard Institute of Proteomics. Information related to the use of Gateway^? Clones can be obtained from Invitrogen?. Recombination was facilitated through an attB substrate (attB-PCR product or a linearized attB expression clone) with an attP substrate (pDONR?221) to create an attL-containing entry clone. The entry clone contains recombinational cloning sites, attL1 and attL2 to facilitate gene transfer into a destination vector, M13 forward and reverse priming sites for sequencing and a kanamycin resistance gene for selection. Please refer to the Invitrogen? Gateway^? Technology Manual for additional details. Plate orientation and viability were confirmed for NR-19718. Each inoculated well of the 96-well plate contains approximately 60 ?L of E. coli culture (strain DH10B-T1) in Luria Bertani (LB) broth containing 50 ?g/mL kanamycin supplemented with 15% glycerol.

NR-19636?? Yersinia pestis, Strain KIM, Gateway? Clone Set, Recombinant in Escherichia coli, Plate 40(Clones)|Yersinia pestis|Yersinia pestis, Strain KIM, Gateway? Clone Set, Recombinant in Escherichia coli, Plate 40|-80°C or colder|Pathogen Functional Genomics Resource Center at the J. Craig Venter InstituteAcknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Yersinia pestis, Strain KIM, Gateway^? Clone Set, Recombinant in Escherichia coli, Plate 40, NR-19636."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.The Yersinia pestis (Y. pestis), strain KIM, Gateway^? clone set consists of 43 plates (plate 2 of this clone set has been discontinued) which contain more than 3600 sequence validated clones from Y. pestis, strain KIM cloned in Escherichia coli (E. coli) DH10B-T1 cells. Each open reading frame was constructed in vector pDONR?221 (Invitrogen?) with an ATG start codon and a TAG stop codon. The sequence was validated by full length sequencing of each clone with greater than 1X coverage and a mutation rate of less than 0.2%.Information related to the use of Gateway^? Clones can be obtained from Invitrogen?. Recombination was facilitated through an attB substrate (attB-PCR product or a linearized attB expression clone) with an attP substrate (pDONR?221) to create an attL-containing entry clone. The entry clone contains recombinational cloning sites, attL1 and attL2 to facilitate gene transfer into a destination vector, M13 forward and reverse priming sites for sequencing and a kanamycin resistance gene for selection. Please refer to the Invitrogen? Gateway^?Technology Manual for additional details.Each inoculated well of the 96-well plate contains approximately 60 ?L of E. coli culture (strain DH10B-T1) in Luria Bertani (LB) Broth containing 50 ?g/mL kanamycin supplemented with 15% glycerol.Note: Production in the 96-well format has increased risk of cross-contamination between adjacent wells. Individual clones should be purified (e.g. single colony isolation and purification using good microbiological practices) and sequence-verified prior to use. BEI Resources cannot confirm or validate any clone not identified on the plate information table found on the Product Information Sheet.